Skip to main content

Table 1 Baseline Characteristics of Healthy Living After Cancer (HLaC) participants overall and by Cancer Council

From: Translating research into practice: outcomes from the Healthy Living after Cancer partnership project

Overall Overall A B C D p a
n Summary n Summary n Summary n Summary n Summary
Age (M ± SD) 786 57.52 ± 11.44 248 57.43 ± 11.74 170 58.26 ± 10.52 200 55.34 ± 11.63 168 59.52 ± 11.29 0.004
 Male 94 12.0% 32 12.9% 16 9.4% 29 14.5% 17 10.1% 0.384
 Female 692 88.0% 216 87.1% 154 90.6% 171 85.5% 151 89.9%  
Ethnicity            0.006 b
 Aboriginal or Torres Strait Islander 7 0.9% 5 2.0% 1 0.6% 1 0.5% 0 0.0%  
 Asian 39 5.0% 14 5.6% 3 1.8% 13 6.5% 9 5.4%  
 Caucasian or white 705 89.7% 212 85.5% 162 95.3% 179 89.50% 152 90.5%  
 Middle Eastern 9 1.1% 3 1.2% 2 1.2% 3 1.5% 1 0.6%  
 Pacific Islander 7 0.9% 5 2.0% 0 0.0% 0 0.0% 2 1.2%  
 South American 7 0.9% 5 2.0% 0 0.0% 1 0.5% 1 0.6%  
 Other 10 1.3% 3 1.2% 1 0.6% 3 1.5% 3 1.8%  
 Not reported 2 0.3% 1 0.4% 1 0.6% 0 0.0% 0 0.0%  
Comorbidities
 0 160 20.4% 61 24.6% 29 17.1% 44 22.0% 26 15.5% 0.005
 1 189 24.0% 68 27.4% 38 22.4% 48 24.0% 35 20.8%  
 2 160 20.4% 46 18.5% 41 24.1% 40 20.0% 33 19.6%  
 3 123 15.6% 28 11.3% 30 17.6% 34 17.0% 31 18.5%  
  ≥ 4 154 19.6% 45 18.1% 32 18.8% 34 17.0% 43 25.6%  
Education
  < High School 115 14.6% 34 13.7% 33 19.4% 31 15.4% 17 10.1% 0.004
 High School 71 9.0% 16 6.5% 24 14.1% 19 9.5% 12 7.1%  
 TAFE / Technical 267 34.0% 72 29.0% 57 33.5% 69 34.5% 69 41.1%  
 University 333 42.4% 126 50.8% 56 32.9% 81 40.5% 70 41.7%  
BMI, kg/m2 M ± SD 786 28.81 ± 6.51 248 27.67 ± 6.47 170 30.14 ± 6.52 200 29.05 ± 6.28 168 28.85 ± 6.59 0.002
Employment
 Full time 149 19.0% 48 19.4% 25 14.7% 44 22.0% 32 19.0% 0.261
 Part-time / Casual 231 29.4% 69 27.8% 50 29.4% 61 30.5% 51 30.4%  
 Self employed 13 1.7% 4 1.6% 1 0.6% 5 2.5% 3 1.8%  
 Home duties 62 7.9% 21 8.5% 14 8.2% 15 7.5% 12 7.1%  
 Retired 164 20.9% 57 23.0% 29 17.1% 34 17.0% 44 26.2%  
 Unable to work 104 13.2% 32 12.9% 34 20.0% 24 12.0% 14 8.3%  
 Other not working 63 8.0% 17 6.9% 17 10.0% 17 8.5% 12 7.1%  
Alcohol (standard drinks/ week) c
 0 390 49.6% 120 48.4% 81 47.6% 101 50.5% 88 52.4% 0.867
  > 0 to < 21 370 47.1% 118 47.6% 82 48.2% 96 48.0% 74 44.0%  
 21 to < 35 21 2.7% 8 3.2% 6 3.5% 2 1.0% 5 3.0%  
  ≥ 35 5 0.6% 2 0.8% 1 0.6% 1 0.5% 1 0.6%  
Marital status
 Married / living together 501 63.7% 160 64.5% 109 64.1% 120 60.0% 112 66.7% 0.681
 Divorced 124 15.8% 34 13.7% 30 17.6% 32 16.0% 28 16.7%  
 Separated 31 3.9% 14 5.6% 4 2.4% 7 3.5% 6 3.6%  
 Widowed 34 4.3% 13 5.2% 6 3.5% 10 5.0% 5 3.0%  
 Never married 96 12.2% 27 10.9% 21 12.4% 31 15.5% 17 10.1%  
IRSAD
 Bottom 30% of state 133 17.1% 35 14.1% 35 21.2% 40 20.0% 23 13.9% 0.268
 Middle 40% of state 299 38.5% 93 38.0% 66 40.0% 77 38.5% 63 51.8%  
 Top 30% of state 344 44.3% 117 47.8% 64 38.8% 83 41.5% 80 48.2%  
 Missing 10 3 5 0 2  
Geographic location
 Major City 594 76.3% 198 80.8% 112 67.1% 149 74.5% 135 80.4% 0.005
 Elsewhere 184 23.7% 47 19.2% 55 32.9% 51 25.5% 31 18.7%  
 Missing 8 3 3 0 2  
Years since diagnosis: M ± SD, Median (min, max) 786 1.91 ± 3.02 248 2.11 ± 2.72 170 1.86 ± 2.98 200 1.70 ± 1.95 168 1.92 ± 4.28 0.316
1 (0, 54)   1 (0, 20)   1 (0, 32)   1 (0, 15)   1 (0, 54)  
Cancer type
 Breast 484 61.6% 143 57.7% 113 66.5% 114 56.7% 114 67.9% 0.113 b
 Cervical 12 1.5% 6 2.4% 1 0.6% 4 2.0% 1 0.6%  
 Colorectal / bowel 71 9.0% 18 7.3% 16 9.4% 22 11.0% 15 8.9%  
 Kidney 7 0.9% 2 0.8% 1 0.6% 4 2.0% 0 0.0%  
 Lung 7 0.9% 3 1.2% 0 0.0% 1 0.5% 3 1.8%  
 Lymphoma 66 8.4% 22 8.9% 15 8.8% 17 8.5% 12 7.1%  
 Melanoma 2 0.3% 0 0.0% 0 0.0% 1 0.5% 1 0.6%  
 Prostate 30 3.8% 11 4.4% 7 4.1% 5 2.5% 7 4.2%  
 Stomach 2 0.3% 0 0.0% 0 0.0% 2 1.0% 0 0.0%  
 Testicular 3 0.4% 0 0.0% 1 0.6% 2 1.0% 0 0.0%  
 Ovarian 19 2.4% 10 4.0% 4 2.4% 4 2.0% 1 0.6%  
 Uterine 15 1.9% 2 0.8% 2 1.2% 9 4.5% 2 1.2%  
 Endometrial 10 1.3% 5 2.0% 2 1.2% 2 1.0% 1 0.6%  
 Leukaemia 11 1.4% 5 2.0% 4 2.4% 2 1.0% 0 0.0%  
 Other 47 6.0% 21 8.5% 4 2.4% 11 5.5% 11 6.5%  
Treatment
 Surgery 686 87.3% 208 83.9% 147 86.5% 178 89.0% 153 91.1% 0.140
 Chemotherapy 531 67.6% 166 66.9% 123 72.4% 128 64.0% 114 67.9% 0.389
 Radiotherapy 469 59.7% 155 62.5% 103 60.6% 119 59.5% 92 54.8% 0.465
 Hormone therapy 343 43.6% 105 42.3% 62 36.5% 92 46.0% 84 50.0% 0.073
 trastuzumab 75 9.5% 19 7.7% 22 12.9% 13 6.5% 21 12.5% 0.069
  1. IRSAD index of relative socioeconomic advantage and disadvantage, BMI body mass index
  2. a p for difference between cancer council by ANOVA (M ± SD) or chi-square test (%)
  3. b due to insufficient frequencies chi-square test based on collapsed categories: Caucasian / other; breast / colorectal or bowel / lymphoma / prostate / other
  4. c Measured per week: cut-offs based on daily thresholds of none, > 0 to < 3/day, 3 to < 5 / day, and > =5 /day)